Introducción: La incontinencia es un problema de salud frecuente que afecta la calidad de vida de las personas, limitando la autonomía y reduciendo la autoestima. Entre el 36-54% de las personas con incontinencia severa pueden presentar deterioro moderado a extremo en su cotidianidad y confianza. Objetivo: Evaluar la percepción de pacientes adultos con incontinencia urinaria y/o incontinencia fecal severa frente al uso de los pañales desechables. Metodología: Estudio observacional de cohorte, en pacientes afiliados a programas de atención domiciliaria usuarios de tres marcas comerciales de pañales. La percepción se evaluó con el instrumento ICIQ-PadPROM®. Resultados: Participaron 179 pacientes, 68% mujeres con edad promedio 71,9 años. El dominio de diseño de pañal y efecto físico fue el que presentó mejor calificación, siendo el pañal Content Medical® el mejor calificado, con diferencias significativas principalmente frente al grupo de Rely®; en el ítem de filtraciones del dominio carga del pañal, Content Medical® presenta mejor percepción comparado contra los otros grupos (p<0.001). Conclusiones: Los pacientes tienen adecuada percepción de las marcas de pañal; sin embargo, los que utilizaron Content Medical® refieren mayor percepción favorable.
Objectives: No drugs have yet been FDA-approved to treat non-alcoholic fatty liver disease (NAFLD). Several clinical trials have demonstrated beneficial effects of antidiabetic drugs (i.e., pioglitazone, liraglutide, and exenatide) in treating NAFLD. However, whether diagnosis of NAFLD influences clinicians' choice of antidiabetic agents is unknown. This study assessed the initiation timing of glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and thiazolidinediones (TZDs) relative to a NAFLD diagnosis. Methods: We conducted a retrospective cohort study from 2012-2019 using MarketScan® Explorys® Claims-EMR Data Set. Adult patients with diagnosis of NAFLD who newly initiated GLP-1RAs, DPP-4is, or TZDs were selected from the database. The index date was defined as the initiation date of an antidiabetic agent. NAFLD was identified using the earliest date of diagnosis 365 days before and after the index date. We described the raw frequency distribution of antidiabetic drugs initiation relative to a NAFLD diagnosis. Results: Overall, 4,640 patients with diagnosis of NAFLD contributed 5,180 initiation episodes (n GLP-1RAs = 2,243, n DPP-4is = 2,587, n TZDs = 350). Approximately 60% of the initiations were subsequent to the diagnosis of NAFLD. Among GLP1-RAs, DPP-4is, and TZDs, the distribution of dispensed products was similar before and after the NAFLD diagnosis, with a slight decline in sitagliptin (40.3% prior to NAFLD vs 36.9% after NAFLD) and increase in dulaglutide (10.2% prior to NAFLD vs 12.5% after NAFLD) and linagliptin (7.0% prior to NAFLD vs 8.3% after NAFLD). Conclusions: The preliminary findings from this study suggest that patients are more likely to initiate these GLP-1RAs, DPP-4is, and TZDs after a NAFLD diagnosis. Further analysis will aim to establish the direct effect of a NAFLD diagnosis on the initiation of these drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.